- Home
- ANAB vs ZVRA Comparison
ANAB vs ZVRA Comparison
Compare ANAB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ZVRA
- Stock Information
- Founded
- ANAB 2005
- ZVRA 2006
- Country
- ANAB United States
- ZVRA United States
- Employees
- ANAB N/A
- ZVRA N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- ZVRA Health Care
- Exchange
- ANAB Nasdaq
- ZVRA Nasdaq
- Market Cap
- ANAB 630.2M
- ZVRA 627.7M
- IPO Year
- ANAB 2017
- ZVRA 2015
- Fundamental
- Price
- ANAB $21.90
- ZVRA $8.95
- Analyst Decision
- ANAB Buy
- ZVRA Strong Buy
- Analyst Count
- ANAB 10
- ZVRA 10
- Target Price
- ANAB $48.00
- ZVRA $22.67
- AVG Volume (30 Days)
- ANAB 465.1K
- ZVRA 1.7M
- Earning Date
- ANAB 11-04-2025
- ZVRA 08-12-2025
- Dividend Yield
- ANAB N/A
- ZVRA N/A
- EPS Growth
- ANAB N/A
- ZVRA N/A
- EPS
- ANAB N/A
- ZVRA N/A
- Revenue
- ANAB $123,164,000.00
- ZVRA $62,020,000.00
- Revenue This Year
- ANAB $11.22
- ZVRA $329.57
- Revenue Next Year
- ANAB $8.35
- ZVRA $55.29
- P/E Ratio
- ANAB N/A
- ZVRA N/A
- Revenue Growth
- ANAB 304.17
- ZVRA 161.81
- 52 Week Low
- ANAB $12.21
- ZVRA $6.19
- 52 Week High
- ANAB $40.70
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- ANAB 52.43
- ZVRA 35.11
- Support Level
- ANAB $19.86
- ZVRA $8.65
- Resistance Level
- ANAB $22.98
- ZVRA $9.48
- Average True Range (ATR)
- ANAB 1.00
- ZVRA 0.38
- MACD
- ANAB 0.35
- ZVRA -0.03
- Stochastic Oscillator
- ANAB 69.14
- ZVRA 20.27
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.